• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172041 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
. h3 J6 z  d2 [! F% A( `' m
2 D4 o; c+ Z- {! A, j% G* E7 y8 N3 H: S  e
Sub-category:; I1 ~* z+ m& q- T; f+ J% @
Molecular Targets - X2 }, A" n. Y; U4 _- R  W. N
3 I% {) N; H! Z. z$ [0 F
2 Z3 S7 I3 s# i8 u7 s" K" u
Category:
1 m) M  T! x( A7 a4 t* v2 GTumor Biology
3 ?; p3 O0 i2 n* z' n
: k1 S, d, z* w* Q! o' K. Y; o# s* m; ^- E! ~  Y$ O4 f+ e% `7 ?
Meeting:( c# Z+ r, r( W  M  @6 Q* u
2011 ASCO Annual Meeting # N! l  q: `/ |3 a6 ?
. g! [2 b- p8 Z6 ?/ f  }
5 l% }! |9 i; q$ h& h
Session Type and Session Title:
7 y5 Z$ c* j% W  @Poster Discussion Session, Tumor Biology
0 M7 t6 _2 L$ y" }6 A
0 j3 [  L" Y5 T# Y1 u! x! o  E6 h( B& r( w, v( V+ {- z
Abstract No:. `7 I# ~6 r0 M
10517
  D* L" Z" O+ I. e# ~- V
/ w: ]3 T" M, z8 _1 L" X% X6 P4 a5 O
Citation:
4 `8 s* x4 C: r1 u, z3 }. ]J Clin Oncol 29: 2011 (suppl; abstr 10517)
7 |1 q& W% o; n/ @. I9 ?7 X0 L: k- o, u7 {! t+ c$ u4 k" W
; K$ V7 B/ _7 l9 T% w  v0 [7 q
Author(s):
7 n4 y2 I6 ~' F! TJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " l5 S5 x8 h( t3 _* ~" ~
: I- y( E( ^/ `& g: d
  J* T, T( Z8 Y. A
* p2 k: B3 j0 T: b2 i% r  R
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.. m6 E0 D5 d/ E, o& o: h

: F# Z; B2 p' L& B$ j2 XAbstract Disclosures
* @$ h- x3 n8 t0 C! P2 N
* f+ O0 ~, A+ i7 b" h: p2 ^Abstract:
7 |% z* T) ?% d8 _
2 K& y/ c  {2 \; d" l0 s6 W# {! n- l
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; A7 i  [; v2 f: q3 a5 ^! {
) V. j2 J1 r+ w) i
  z# S6 Z4 o  Z/ V- f
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
0 s7 e, O: w. s" }7 g" o5 L) W没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

, \; C# d1 g( ]( c化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 : s$ I; x, l# _" s5 T4 i
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。5 o9 \) O3 g$ X: L( P
ALK一个指标医院要900多 ...
; v( v) {8 t2 w- c8 w: p
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?, u4 S6 b# e! c6 M& H" `

, L9 p' ~, J! z5 R1 e" M, v现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表